Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
about
Structural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2-SET DomainDiverse involvement of EZH2 in cancer epigeneticsSynthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancersHMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene lociEZH2: not EZHY (easy) to deal.Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing E-cadherin in cervical cancerPrognostic biomarkers in ovarian cancer.Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma.A mathematical model of bimodal epigenetic control of miR-193a in ovarian cancer stem cells3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence.Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysisOncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence.ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approachesSignificance of EZH2 expression in canine mammary tumors.SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK.Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.Role of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic TargetBRG1 is required for formation of senescence-associated heterochromatin foci induced by oncogenic RAS or BRCA1 lossNF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells.Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition3D culture adds an extra dimension to targeted epigenetic therapiesEZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells.Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancerThe role of maintenance proteins in the preservation of epithelial cell identity during mammary gland remodeling and breast cancer initiation.EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy.Restoring TRAIL mediated signaling in ovarian cancer cells.BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.ATM couples replication stress and metabolic reprogramming during cellular senescence.H3K27me3 is an Epigenetic Mark of Relevance in Endometriosis.Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence.Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma.Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cellsEZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers.Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
P2860
Q27681087-4228FE72-D6E4-4C5F-9C4F-1614C908C19EQ28084911-2DF15873-AC29-444C-82DD-B99545DAB276Q28257103-900A2486-EE5A-4B00-AADA-CB7B01F0C559Q28315115-352B9AD9-F44B-4A28-97BA-869E3016C752Q33610902-29463927-FA3B-4835-9303-1326F7AFA1B5Q33875021-102F050B-CFD7-4A34-A3FE-F1180A3C6FECQ34086636-9F7F3F6F-47C6-40F6-9B5C-05F4796BCBFDQ34293217-DB40623C-A277-48A5-8E8C-E6558F447B97Q34784456-2B89F261-F97E-412F-B5D1-7ACAD4B8772DQ35172602-0E0905FB-71EB-462D-B337-3AAA37B8C4B9Q35256323-E3B3D358-A862-44D3-9871-1D308F2E441CQ35606640-1B269581-889A-4BC7-9020-4AA8BED427A1Q35621531-D850F8FB-5D9B-4856-B10F-D2393D95BB62Q35803467-5E6F00FE-4AE5-446C-80E0-9C1EE391BAB7Q36098022-73A7A07F-6B7A-4B1C-8644-152A584DB950Q36409515-7C8CDC57-BA62-4648-A19F-544F36D5708EQ36544065-3A18FAB9-A0FE-4D9B-880D-B2903E7CC164Q36679745-476D54A3-3173-49C5-9CAB-440FCC7B1C64Q36759676-4034A6E6-47A9-43C9-A085-0AF43DEBDDF6Q36780759-87E1A13D-8ECC-4A07-B967-B876970617A0Q36959292-9FD70B77-966F-485C-9EF4-F505A7577C85Q37079770-0E4B0037-057C-4023-8D8A-EF9CB2F54BDDQ37126154-FE3E8C1F-27D4-4505-827B-2552C9FBCB97Q37362586-998DDD0E-0ED7-4938-8950-1330C5CC160AQ37529964-25327FCC-0AEA-4173-A1F0-2F8BC5E58EEEQ37603631-7E142B8E-F1D5-435F-9740-9BE8BE14A249Q37636628-99C4B567-171B-4791-8CBA-79F6946E50D5Q37708968-3FA756D2-6319-4836-9483-8A9DEA8C55F9Q37911312-EB7B275B-D44E-4654-A391-213DA1EED635Q38230205-30DD101E-ACE9-4AAE-A170-BB924B49F244Q38734234-02B3B1A5-269B-4DEC-9447-AD210EB30306Q38879504-B801F8CA-584A-4400-8532-8FDD88A35D2BQ38893487-7A7FD30F-52CE-4DA6-8C80-B433550E52E4Q39170489-6C728224-0164-4500-9394-6D1CD6BB16A5Q39459774-38F7BA26-44B2-429B-A4EE-24BEF944425DQ41105052-DC70DDFC-CDE9-4EBC-8BBE-9E225F067E4AQ42577888-70E0ADE8-B407-42C7-B51D-C9FE092D9C06Q46095043-BEFD3402-0C1D-4511-B9C9-8601E7E74A44Q47931449-648C7ED6-7DBD-45EF-A95E-6F256897F44DQ48325256-1C8D132A-CC89-4377-A617-D0FAC9C08484
P2860
Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Enhancer of zeste homolog 2 pr ...... ithelial ovarian cancer cells.
@ast
Enhancer of zeste homolog 2 pr ...... ithelial ovarian cancer cells.
@en
Enhancer of zeste homolog 2 pr ...... ithelial ovarian cancer cells.
@nl
type
label
Enhancer of zeste homolog 2 pr ...... ithelial ovarian cancer cells.
@ast
Enhancer of zeste homolog 2 pr ...... ithelial ovarian cancer cells.
@en
Enhancer of zeste homolog 2 pr ...... ithelial ovarian cancer cells.
@nl
prefLabel
Enhancer of zeste homolog 2 pr ...... ithelial ovarian cancer cells.
@ast
Enhancer of zeste homolog 2 pr ...... ithelial ovarian cancer cells.
@en
Enhancer of zeste homolog 2 pr ...... ithelial ovarian cancer cells.
@nl
P2093
P2860
P1476
Enhancer of zeste homolog 2 pr ...... ithelial ovarian cancer cells.
@en
P2093
Andrew K Godwin
Rugang Zhang
P2860
P304
P356
10.1158/1541-7786.MCR-10-0398
P577
2010-11-29T00:00:00Z